CMS on July 2 announced its finalized national coverage policy for ambulatory blood pressure monitoring—one that extends coverage to patients with suspected masked hypertension and aligns CMS’ BP thresholds with the latest society guidelines.

A lack of formal training in nutrition could significantly limit how physicians practice, according to an editorial published in JAMA Internal Medicine this month, in some cases leading them to recommend risky treatments to patients in lieu of dietary counseling that might be just as effective.

A bariatric surgeon at the Ohio State Wexner Medical Center is advocating for a new set of clinical guidelines that would extend eligibility for weight loss surgery to thousands more patients struggling with their weight.

Fear-based “fake news” about statin therapy is driving non-adherence to the drugs in the U.S., according to an editorial published in JAMA Cardiology June 26, fostering a culture of mistrust and misinformation that could easily deter heart patients from a treatment that might be beneficial to them.

Body fat distribution could be a key predictor of heart disease risk in postmenopausal women, according to a July 1 study that found “apple”-shaped women are more prone to CVD than their “pear”-shaped counterparts.

Sportswear brand Under Armour filed a patent application this week for a new “smart” shoe that’s able to take a wearer’s blood pressure and help them recover faster from a workout.

Patients prescribed statins for CV risk reduction are more than twice as likely to develop type 2 diabetes compared to non-statin users, a study out of Ohio State University has found.

Online pharmacy Valisure on June 13 issued a letter to the FDA after in-house testing revealed dangerously elevated levels of N,N-Dimethylformamide (DMF) in certain lots of valsartan, an angiotensin II receptor blocker (ARB) commonly used to treat hypertension and heart failure.